Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Shire goes hostile on Baxter spin-out Baxalta

Fresh from announcing that the company will acquire Foresight BioTherapeutics for $300m (here), Shire stepped up its ambitions to acquire the recently spun-out Baxalta, which went public earlier this summer (here). Shire originally approached the Baxalta Board of Directors earlier in July about the coming together of the the two companies, since when the Baxalta Board have been ignoring Shire’s advances, which has promoted Shire to go public with its $30.6bn all-stock offer. This hostile move is aimed at drawing out Baxalta shareholders in an attempt to push the Board to enter negotiations. Shire held an investor call today where it laid out its rationale for the deal and articulated how it would allow the company to reach a $20bn revenue company by 2020 and become the undisputed rare disease leader (here).

Read the full article…

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , | Leave a comment

Shire Eyes Smaller Deal in Shopping Spree

In the recent analyst call for Shire’s Q2 results, CEO Flemming Ornskov suggested that the company was still scouting for acquisitions which would bolster the pipeline in the strategic areas he has set out as priorities. Cognizant that valuations are looking stretched in some areas of biotech, not least rare diseases, the Shire philosophy was seemingly was to look for good value.

Read the full article…

Posted in M&A Finance and Funding | Tagged , , , , , , | Leave a comment

M&A Continues to Dominate the Rare Diseases Landscape

Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.

Read the full article…

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

13 Life Science Leaders to watch in 2013 – The Verdict!

Authored by Liftstream

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Shire appoints new Chairwoman to Board and closes Viropharma acquisition

Authored by Karl Simpson

Read the full article…

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , | Leave a comment

Shire expands rare disease reach with Viropharma Purchase

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Onyx deal signals broader interest in orphan drugs

Authored by Karl Simpson

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Shire starts year with flurry of deals

Authored by James Sheppard

Read the full article…

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , | Leave a comment

13 Life Science Leaders to watch in 2013

Authored by Liftstream

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Shire Pharmaceuticals CEO, Angus Russell, announces departure and sucessor

Authored by Karl Simpson

Read the full article…

Posted in Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap